These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 27716285)

  • 21. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
    Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
    Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
    Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
    J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
    Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
    Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
    Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
    Cui Q; Hu Y; Ma D; Liu H
    Drug Des Devel Ther; 2021; 15():339-347. PubMed ID: 33536747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.
    Dittrich C; Fridrik MA; Koenigsberg R; Lee C; Goeldner RG; Hilbert J; Greil R
    Invest New Drugs; 2015 Apr; 33(2):409-22. PubMed ID: 25529193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
    Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
    BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
    Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
    Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
    Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
    J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
    Yap TA; Arkenau HT; Camidge DR; George S; Serkova NJ; Gwyther SJ; Spratlin JL; Lal R; Spicer J; Desouza NM; Leach MO; Chick J; Poondru S; Boinpally R; Gedrich R; Brock K; Stephens A; Eckhardt SG; Kaye SB; Demetri G; Scurr M
    Clin Cancer Res; 2013 Feb; 19(4):909-19. PubMed ID: 23403628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
    Tabernero J; Bahleda R; Dienstmann R; Infante JR; Mita A; Italiano A; Calvo E; Moreno V; Adamo B; Gazzah A; Zhong B; Platero SJ; Smit JW; Stuyckens K; Chatterjee-Kishore M; Rodon J; Peddareddigari V; Luo FR; Soria JC
    J Clin Oncol; 2015 Oct; 33(30):3401-8. PubMed ID: 26324363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.